- Home
- INMB vs MAIA Comparison
INMB vs MAIA Comparison
Compare INMB & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- MAIA
- Stock Information
- Founded
- INMB 2015
- MAIA 2018
- Country
- INMB United States
- MAIA United States
- Employees
- INMB N/A
- MAIA N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- INMB Health Care
- MAIA Health Care
- Exchange
- INMB Nasdaq
- MAIA Nasdaq
- Market Cap
- INMB 49.2M
- MAIA 44.9M
- IPO Year
- INMB 2019
- MAIA 2022
- Fundamental
- Price
- INMB $1.87
- MAIA $1.41
- Analyst Decision
- INMB Hold
- MAIA
- Analyst Count
- INMB 3
- MAIA 0
- Target Price
- INMB $4.30
- MAIA N/A
- AVG Volume (30 Days)
- INMB 349.2K
- MAIA 1.0M
- Earning Date
- INMB 10-30-2025
- MAIA 11-07-2025
- Dividend Yield
- INMB N/A
- MAIA N/A
- EPS Growth
- INMB N/A
- MAIA N/A
- EPS
- INMB N/A
- MAIA N/A
- Revenue
- INMB $50,000.00
- MAIA N/A
- Revenue This Year
- INMB $264.29
- MAIA N/A
- Revenue Next Year
- INMB $9,819.61
- MAIA N/A
- P/E Ratio
- INMB N/A
- MAIA N/A
- Revenue Growth
- INMB N/A
- MAIA N/A
- 52 Week Low
- INMB $1.71
- MAIA $1.26
- 52 Week High
- INMB $11.64
- MAIA $3.48
- Technical
- Relative Strength Index (RSI)
- INMB 45.15
- MAIA 44.19
- Support Level
- INMB $1.79
- MAIA $1.38
- Resistance Level
- INMB $1.95
- MAIA $1.57
- Average True Range (ATR)
- INMB 0.10
- MAIA 0.10
- MACD
- INMB 0.01
- MAIA -0.00
- Stochastic Oscillator
- INMB 46.00
- MAIA 32.58
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.